According to the World Health Organization (WHO), obesity is one of the greatest health risks. With increasing severity, the risk of various concomitant and secondary diseases increases
. Obesity-related multimorbidity is complex, and weight reduction can have a health-promoting effect at various levels. Today, five therapeutic pillars are available for the treatment of obesity, including drug interventions using incretin analogs such as semaglutide and tirzepatide.
Publikation
- HAUSARZT PRAXIS